ROCKET DOCTOR AI INC. ANNOUNCES AUTOMATIC CONVERSION OF SPECIAL WARRANTS

Rhea-AI Summary

Rocket Doctor AI (CSE: AIDR) has announced the automatic conversion of 3,677,400 special warrants into common shares and warrants. The company filed a prospectus supplement on September 22, 2025, qualifying the distribution of securities in British Columbia, Alberta, and Ontario.

Each warrant allows holders to purchase one common share at $0.75 per share for 12 months from issuance. The special warrants will automatically convert on October 2, 2025, with no action required from holders. The securities are not registered under U.S. securities law and cannot be offered or sold in the United States without registration or exemption.

Positive

• Automatic conversion of 3,677,400 special warrants provides additional capital structure clarity
• No action required from warrant holders for conversion, streamlining the process
• Multi-province qualification in major Canadian markets (BC, Alberta, Ontario)

Negative

• Potential dilution from the conversion of 3,677,400 special warrants and additional warrants
• Limited to 12-month exercise period for warrants
• Securities not registered for U.S. trading, limiting potential investor base

Vancouver, British Columbia, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (the “Company” or “Rocket Doctor AI”) (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) announces that it has filed a prospectus supplement dated September 22, 2025 (the “Prospectus Supplement”) to its short form base shelf prospectus dated June 10, 2024 (the “Shelf Prospectus”) to qualify the distribution of securities underlying 3,677,400 special warrants (the “Special Warrants”) issued by the Company on August 21, 2025 (the “Offering”).

The Prospectus Supplement qualifies the distribution of 3,677,400 common shares (each a “Common Share”) and 3,677,400 common share purchase warrants (each a “Warrant”) comprising the units of the Company issuable on the exercise or deemed exercise of the Special Warrants in the Provinces of British Columbia, Alberta, and Ontario. Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of $0.75 until 5:00 p.m. (Pacific Time) for a period of 12 months from the date of issuance.

The Special Warrants will be deemed to be converted into Common Shares and Warrants on October 2, 2025. No action is required on the part of any holder of Special Warrants to convert their Special Warrants into underlying securities.

The qualification rights of holders of Special Warrants are further described in the Prospectus Supplement and the Shelf Prospectus, which can be found under the Company’s profile on SEDAR+ at a www.sedarplus.ca. 

Access to the Shelf Prospectus and the Prospectus Supplement, and any amendment to the documents, is provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Shelf Prospectus and the Prospectus Supplement are accessible on SEDAR+ at www.sedarplus.ca. An electronic or paper copy of the Prospectus Supplement, the corresponding Shelf Prospectus and any amendment to the documents may be obtained, without charge, from the Company by email at info@rocketdoctor.ai and by providing the contact with an email address or address, as applicable.

The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Rocket Doctor AI Inc.

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high- quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.

Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 300 MDs to provide care to more than 700,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.

To learn more about Rocket Doctor AI Inc’s products and services, contact: www.rocketdoctor.ai or email: info@rocketdoctor.ai

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO, Rocket Doctor AI essam.hamza@rocketdoctor.ai

Dr. Bill Cherniak, CEO, Rocket Doctor Inc. bill@rocketdoctor.io

For media inquiries, contact: media@rocketdoctor.ai Call: +1 (778) 819 8321

Cautionary Statements

This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Offering, the use of proceeds of the Offering, the filing of a Prospectus Supplement and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward- looking statements as expressly required by Canadian securities law.

Holly Iervella

FAQ

When will Rocket Doctor AI's special warrants convert to common shares?

The special warrants will automatically convert into common shares and warrants on October 2, 2025.

How many special warrants of Rocket Doctor AI (CSE: AIDR) will be converted?

3,677,400 special warrants will be converted into an equal number of common shares and warrants.

What is the exercise price for Rocket Doctor AI's warrants?

Each warrant can be exercised to acquire one common share at $0.75 for 12 months from the date of issuance.

In which provinces are Rocket Doctor AI's securities qualified for distribution?

The securities are qualified for distribution in the provinces of British Columbia, Alberta, and Ontario.

Can U.S. investors trade Rocket Doctor AI's special warrants?

No, the securities are not registered under U.S. securities law and cannot be offered or sold in the United States without registration or an applicable exemption.